{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:38:28Z","timestamp":1775871508336,"version":"3.50.1"},"reference-count":68,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. bras. pneumol."],"abstract":"<jats:p>ABSTRACT Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M\/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. Treating M\/XDR-TB continues to be a difficult task, because of the high incidence of adverse events, the long duration of treatment, the high cost of the regimens used, and the drain on health care resources. Various trials and studies have recently been undertaken (some already published and others ongoing), all aimed at improving outcomes of M\/XDR-TB treatment by changing the overall approach, shortening treatment duration, and developing a universal regimen. The objective of this review was to summarize what has been achieved to date, as far as new and repurposed drugs are concerned, with a special focus on delamanid, bedaquiline, pretomanid, clofazimine, carbapenems, and linezolid. After more than 40 years of neglect, greater attention has recently been paid to the need for new drugs to fight the \u201cwhite plague\u201d, and promising results are being reported.<\/jats:p>","DOI":"10.1590\/s1806-37562017000000436","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T16:46:32Z","timestamp":1526748392000},"page":"153-160","source":"Crossref","is-referenced-by-count":53,"title":["New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis"],"prefix":"10.1590","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0230-2734","authenticated-orcid":false,"given":"Denise Rossato","family":"Silva","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul,  Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-1082","authenticated-orcid":false,"given":"Margareth","family":"Dalcolmo","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9424-6551","authenticated-orcid":false,"given":"Simon","family":"Tiberi","sequence":"additional","affiliation":[{"name":"Royal London Hospital,  United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3556-6875","authenticated-orcid":false,"given":"Marcos Abdo","family":"Arbex","sequence":"additional","affiliation":[{"name":"Secretaria de Estado da Sa\u00fade do Estado de S\u00e3o Paulo,  Brasil; Universidade de Araraquara,  Brasil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8453-3634","authenticated-orcid":false,"given":"Marcela","family":"Munoz-Torrico","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Enfermedades Respiratorias,  M\u00e9xico"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3099","authenticated-orcid":false,"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[{"name":"Centro Hospitalar de Vila Nova de Gaia-Espinho,  Portugal; Instituto de Sa\u00fade P\u00fablica,  Portugal; Universidade do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-5777","authenticated-orcid":false,"given":"Lia","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico,  Italia; Public Health Consulting Group,  Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-1623","authenticated-orcid":false,"given":"Dina","family":"Visca","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico,  Italia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8973-4024","authenticated-orcid":false,"given":"Adrian","family":"Rendon","sequence":"additional","affiliation":[{"name":"Universidad de Monterrey,  Mexico"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9949-6012","authenticated-orcid":false,"given":"Mina","family":"Gaga","sequence":"additional","affiliation":[{"name":"Athens Chest Hospital,  Greece"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-5735","authenticated-orcid":false,"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[{"name":"UCL Hospitals NHS Foundation Trust,  United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-574X","authenticated-orcid":false,"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico,  Italia"}]}],"member":"530","published-online":{"date-parts":[[2018,4]]},"reference":[{"key":"ref1","series-title":"Global tuberculosis report 2017","year":"2017"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov SE","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1183\/09031936.00136312","article-title":"Drug resistance beyond extensively drug-resistant tuberculosis individual patient data meta-analysis","volume":"42","author":"Migliori GB","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon D","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1183\/13993003.00649-2015","article-title":"Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment","volume":"46","author":"Winters N","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/09031936.00204611","article-title":"Tuberculosis cost of illness in Germany","volume":"40","author":"Diel R","year":"2012","journal-title":"Eur Respir J"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.00079413","article-title":"Costs of tuberculosis disease in the European Union a systematic analysis and cost calculation","volume":"43","author":"Diel R","year":"2014","journal-title":"Eur Respir J"},{"key":"ref8","article-title":"Team approach to manage difficult-to-treat TB cases: experiences in Europe and beyond","author":"D'Ambrosio L","year":"2017","journal-title":"Rev Port Pneumol (2006)"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1183\/09031936.00196712","article-title":"Supporting TB clinicians managing difficult cases the ERS\/WHO Consilium","volume":"41","author":"Blasi F","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00648-2017","article-title":"Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases","volume":"50","author":"Caminero JA","year":"2017","journal-title":"Eur Respir J"},{"key":"ref11"},{"key":"ref12"},{"key":"ref13","series-title":"Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis","year":"2017"},{"issue":"55","key":"ref14","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1128\/AAC.00699-11","article-title":"Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation","author":"Lu Y","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02445-2016","article-title":"Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil","volume":"49","author":"Dalcolmo M","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1183\/13993003.00214-2016","article-title":"Comparison of effectiveness and safety of imipenem\/clavulanate- versus meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi S","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1183\/13993003.02146-2015","article-title":"Effectiveness and safety of meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi S","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1513236","article-title":"\u00df-Lactams against Tuberculosis--New Trick for an Old Dog","volume":"375","author":"Diacon AH","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1183\/13993003.01278-2015","article-title":"Ertapenem in the treatment of multidrug-resistant tuberculosis first clinical experience","volume":"47","author":"Tiberi S","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1183\/09031936.00145014","article-title":"Linezolid to treat MDR-\/XDR-tuberculosis available evidence and future scenarios","volume":"45","author":"Sotgiu G","year":"2015","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-pharmtox-010617-052438","article-title":"The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development Unraveling the Black Box","volume":"58","author":"Te Brake LHM","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics6010003","article-title":"Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action","volume":"6","author":"Amaral K","year":"2017","journal-title":"Antibiotics"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/13993003.01891-2015","article-title":"Bedaquiline and multidrug-resistant tuberculosis a systematic and critical analysis of the evidence","volume":"47","author":"Pontali E","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00146-2017","article-title":"Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline","volume":"49","author":"Pontali E","year":"2017","journal-title":"Eur Respir J"},{"key":"ref25","series-title":"Country Updates"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence","volume":"50","author":"Pontali E","year":"2017","journal-title":"Eur Respir J"},{"key":"ref27","series-title":"A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis; Identifier NCT02333799; [about 13 screens]","year":"2000"},{"key":"ref28","author":"Conradie F","year":"2017"},{"key":"ref29","series-title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (STREAM); Identifier NCT02409290","year":"2000"},{"key":"ref30","series-title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (NEXT)","year":"2000"},{"key":"ref31","series-title":"Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (TB-PRACTECAL)","year":"2000"},{"key":"ref32","series-title":"Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB)","year":"2000"},{"key":"ref33","author":"Dawson R","year":"2017"},{"key":"ref34","series-title":"Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive\/Intolerant MDR-TB (ZeNix)","year":"2000"},{"key":"ref35","series-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","year":"2014"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1183\/13993003.00705-2016","article-title":"Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis early experiences and challenges","volume":"48","author":"Tadolini M","year":"2016","journal-title":"Eur Respir J"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis","volume":"41","author":"Skripconoka V","year":"2013","journal-title":"Eur Respir J"},{"key":"ref38","series-title":"New Treatments for Drug-Resistant TB Get a Boost","author":"McKay B","year":"2017"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01105-2017","article-title":"Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens","volume":"50","author":"Kuksa L","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00311-2017","article-title":"Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use","volume":"50","author":"Hafkin J","year":"2017","journal-title":"Eur Respir J"},{"key":"ref41","author":"Hafkin J","year":"2015"},{"key":"ref42","author":"Hafkin J","year":"2015"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","DOI":"10.3201\/eid2310.170834","article-title":"Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis","volume":"23","author":"Maryandyshev A","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1183\/13993003.00637-2016","article-title":"First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline","volume":"48","author":"Tadolini M","year":"2016","journal-title":"Eur Respir J"},{"key":"ref45","series-title":"Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis; Identifier NCT02583048","year":"2000"},{"key":"ref46","series-title":"WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis","year":"2017"},{"key":"ref47","series-title":"Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation","year":"2015"},{"issue":"1","key":"ref48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.arbres.2017.06.009","article-title":"Effect of Isoniazid Resistance on the Tuberculosis Treatment Outcome","volume":"54","author":"Santos G","year":"2018","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"ref49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Treatment of isoniazid-resistant tuberculosis with first- line drugs a systematic review and meta-analysis","volume":"17","author":"Gegia M","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5588\/ijtld.16.0716","article-title":"Isoniazid-resistant tuberculosis a cause for concern?","volume":"21","author":"Stagg HR","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"ref51","doi-asserted-by":"crossref","first-page":"832","DOI":"10.5588\/ijtld.15.0577","article-title":"A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis","volume":"20","author":"Jindani A","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis a multi-arm, multi-stage randomized controlled trial","volume":"17","author":"Boeree MJ","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"ref53","series-title":"BTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens (S31\/A5349)","year":"2000"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijid.2016.02.863","article-title":"TRUNCATE-TB an innovative trial design for drug-sensitive tuberculosis","volume":"45","author":"Papineni P","year":"2016","journal-title":"Int J Infect Dis"},{"key":"ref55","first-page":"135","article-title":"Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis Int J Infect","volume":"65","author":"Lee H","year":"2017","journal-title":"Dis"},{"key":"ref56","series-title":"Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (Opti-Q)","year":"2000"},{"key":"ref57","series-title":"Treatment Shortening of MDR-TB Using Existing and New Drugs (MDR-END)","year":"2000"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung K","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardized short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello A","year":"2014","journal-title":"Int J Tuber Lung Dis"},{"issue":"10037","key":"ref60","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0140-6736(16)30729-2","article-title":"WHO recommendations on shorter treatment of multidrug-resistant tuberculosis","volume":"387","author":"Sotgiu G","year":"2016","journal-title":"Lancet"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijid.2016.10.021","article-title":"Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings","volume":"56","author":"Sotgiu G","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"5","key":"ref62","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/13993003.01249-2016","article-title":"Faster for less the new \"shorter\" regimen for multidrug-resistant tuberculosis","volume":"48","author":"Sotgiu G","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"ref63","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00061-2017","article-title":"Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses","volume":"50","author":"Ahmad Khan F","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"ref64","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00463-2017","article-title":"Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe","volume":"49","author":"van der Werf MJ","year":"2017","journal-title":"Eur Respir J"},{"issue":"3","key":"ref65","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00081-2017","article-title":"Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated","volume":"49","author":"Yassin MA","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"ref66","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201701-0013LE","article-title":"Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria","volume":"196","author":"Barry PM","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"ref67","article-title":"The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible","volume":"50","author":"Chee CBE","year":"2017","journal-title":"Eur Respir J"},{"key":"ref68","series-title":"Preliminary results from STREAM trial provide insight into shorter treatment for multidrug-resistant tuberculosis [about 3 screens]","year":"2014"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/jbpneu\/v44n2\/1806-3756-jbpneu-44-02-00153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T16:05:57Z","timestamp":1533139557000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1806-37132018000200153&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,4]]}},"alternative-id":["S1806-37132018000200153"],"URL":"https:\/\/doi.org\/10.1590\/s1806-37562017000000436","relation":{},"ISSN":["1806-3756","1806-3713"],"issn-type":[{"value":"1806-3756","type":"electronic"},{"value":"1806-3713","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}